A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a natural defense system in bacteria that scientists have adapted into a powerful gene-editing tool. This ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...

This California high school features multi-hour labs that blend topics and the curriculum is tailored to students’ interests.

Three copies of chromosome 21 cause Down syndrome (DS), and roughly half of children born each year in the United States with ...

Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s, ALS, and spinocerebellar ataxia are becoming more prevalent as populations age, posing major global health challenges.

Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the ...